SANUWAVE Announces Record Quarterly Revenues: Q2 FY2024 Financial Results

Rhea-AI Summary

SANUWAVE Health (OTCQB: SNWV) reported record quarterly revenues for Q2 FY2024. Key highlights include:

- Q2 2024 revenues of $7.2 million, up 53% year-over-year
- Gross margin of 73%, slightly down from 74% in Q2 2023
- GAAP Operating Income of $2.0 million
- Net income of $6.6 million, compared to a net loss of $7.3 million in Q2 2023
- Adjusted EBITDA of $1.5 million, up from $171,000 in Q2 2023
- 72 UltraMist® systems sold, up from 49 in Q2 2023
- UltraMist® consumables revenue increased by 67% to $4.7 million

The company provided guidance for Q3 2024, expecting revenue growth of 65-75% compared to Q3 2023. SANUWAVE also secured approval for a reverse stock split and 100% participation in its note and warrant exchange offer.

Positive

• Record quarterly revenue of $7.2 million, up 53% year-over-year
• GAAP Operating Income of $2.0 million, an improvement of $1.1 million from Q2 2023
• Net income of $6.6 million, compared to a net loss of $7.3 million in Q2 2023
• Adjusted EBITDA improved to $1.5 million from $171,000 in Q2 2023
• UltraMist® consumables revenue increased by 67% to $4.7 million
• 72 UltraMist® systems sold, up from 49 in Q2 2023
• Guidance for Q3 2024 revenue growth of 65-75% compared to Q3 2023

Negative

• Slight decrease in gross margin from 74% in Q2 2023 to 73% in Q2 2024

Q2 2024 revenues were $7.2 million, up 53% from Q2 2023. This was an all-time quarterly record for the Company.

Q2 2024 Gross Margin was 73%, vs 74% in Q2 2023

GAAP Operating Income was $2.0 Million

Company Provides Guidance for Revenue Growth of 65-75% for Q3 2024 Versus Q3 2023

EDEN PRAIRIE, MN, Aug. 13, 2024 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three months ended June 30, 2024.

Q2 2024 ended June 30, 2024

• Revenue for the three months ended June 30, 2024, totaled $7.2 million, an increase of 53%, as compared to $4.7 million for the same period of 2023.  This growth is within the previous guidance for a 45 – 55% increase.
• 72 UltraMist® systems were sold in Q2 2024 up from 49 in Q2 2023 and from 43 in Q1 2024.
• UltraMist® consumables revenue increased by 67% to $4.7 million (65% of revenues) in Q2 2024, versus $2.8 million for the same quarter last year. UltraMIST systems and consumables remained the primary revenue growth driver and continued to represent in excess of 95% of SANUWAVE’s overall revenues in Q2 2024.
• Gross margin as a percentage of revenue amounted to 73% for the three months ended June 30, 2024, versus 74% for the same period last year, despite some additional costs from standing up new contract manufacturers.
• For the three months ended June 30, 2024, operating income totaled $2.0 million, an improvement of $1.1 million compared to Q2 2023 as a result of the Company’s continued efforts to drive profitable growth and manage expenses.
• Net income for the second quarter of 2024 was $6.6 million, driven predominantly by the change in the fair value of derivative liabilities and the extinguishment of debt.  This compares to a net loss of $7.3 million in the second quarter of 2023.  Net income year to date was $2.2 million versus a net loss of $20.4 million in the first half of 2023.
• Adjusted EBITDA ^[1] for the three months ended June 30, 2024, was $1.5 million versus an Adjusted EBITDA of $171 thousand for the same period last year, an improvement of $1.3 million.  Year to date Adjusted EBITDA was $1.4 million versus a loss of $1.6 million in the first 6 months of the prior year.

“The second quarter mirrored the first with 53% revenue growth year-over-year, which led to an all-time record quarter despite the typical seasonal slowness of the first half of the year,” said Morgan Frank, CEO.  “We’re particularly pleased to have achieved both operating and Adjusted EBITDA positivity for the quarter in pursuit of our strategy of rapid, profitable growth.  As can be seen from our guidance, we expect our growth rate versus prior year periods to further accelerate in Q3 as we seek to continue to gain traction in our markets, ramp up to serve larger customers, and increase our patient counts.  We have continued to hire new salespeople and will continue this trend for the foreseeable future.  We continue to aim for 2024 to be the breakout year for SANUWAVE and feel good about our progress so far.”

Financial Outlook

The Company forecasts Q3 2024 revenue to rise 65-57% vs Q3 2023 ($8-8.5 million of revenues) and for gross margin as a percentage of revenue to remain in the mid 70s.

The Company has now achieved stockholder approval for its proposed reverse stock split and anticipates undertaking this process in the near future.

SANUWAVE has also secured 100% participation in its note and warrant exchange offer, which will be triggered by effecting the reverse stock split and result in the exchange of a significant amount of warrants and convertible promissory notes for shares of common stock, simplifying the Company’s capital structure.

As previously announced, a business update will occur via conference call on August 13, 2024 at 8:30 a.m. EST. Materials for the conference call are included on the Company’s website at

http://www.sanuwave.com/investors

Telephone access to the call will be available by dialing the following numbers:

Participant Listening: 1-800-579-2543 or 1-785-424-1789

OR click the link for instant telephone access to the event.

https://viavid.webcasts.com/starthere.jsp?ei=1684060&tp_key=35ff7216a3
A replay will be made available through September 3, 2024:
Toll-Free: 1-844-512-2921 or 1-412-317-6671
Replay Access ID: 11156749

^[1] This is a non-GAAP financial measure. Refer to “Non-GAAP Financial Measures” and the reconciliations in this release for further information.

About SANUWAVE

SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.

SANUWAVE's end-to-end wound care portfolio of regenerative medicine products and product candidates helps restore the body’s normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.

Non-GAAP Financial Measures

This press release includes certain financial measures that are not presented in our financial statements prepared in accordance with accounting principles generally accepted in the United States (U.S.) (“U.S. GAAP”). These financial measures are considered "non-GAAP financial measures" and are intended to supplement, and should not be considered as superior to, or a replacement for, financial measures presented in accordance with U.S. GAAP.

The Company uses Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) and Adjusted EBITDA to assess its operating performance. Adjusted EBITDA is Earnings before Interest, Taxes, Depreciation and Amortization adjusted for the change in fair value of derivatives and any significant non-cash or infrequent charges.  EBITDA and Adjusted EBITDA should not be considered as alternatives to net income (loss) as a measure of financial performance or any other performance measure derived in accordance with GAAP, and they should not be construed as an inference that the Company’s future results will be unaffected by unusual or infrequent items. These non-GAAP financial measures are presented in a consistent manner for each period, unless otherwise disclosed. The Company uses these measures for the purpose of evaluating its historical and prospective financial performance, as well as its performance relative to competitors. These measures also help the Company to make operational and strategic decisions. The Company believes that providing this information to investors, in addition to GAAP measures, allows them to see the Company’s results through the eyes of management, and to better understand its historical and future financial performance. These non-GAAP financial measures are also frequently used by analysts, investors, and other interested parties to evaluate companies in our industry, when considered alongside other GAAP measures.

EBITDA and Adjusted EBITDA have their limitations as analytical tools, and you should not consider them in isolation or as a substitute for analysis of the Company’s results as reported under GAAP. Some of these limitations are that EBITDA and Adjusted EBITDA:

• Do not reflect every expenditure, future requirements for capital expenditures or contractual commitments.
• Do not reflect all changes in our working capital needs.
• Do not reflect interest expense, or the amount necessary to service our outstanding debt.

As presented in the GAAP to Non-GAAP Reconciliations section below, the Company’s non-GAAP financial measures exclude the impact of certain charges that contribute to our net income (loss).

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations and constraints, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with supply chain and production constraints, regulatory oversight, the Company’s ability to manage its capital resource issues, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

Contact: investors@sanuwave.com

SELECTED FINANCIAL DATA
FOR THE QUARTER ENDED JUNE 30, 2024 AND 2023
(in thousands)					2024				2023
Revenue				$	7,162			$	4,675
Cost of Revenues					1,922				1,202
Gross Margin					5,240				3,473
Gross Margin %					73.2	%			74.3	%
Total operating expenses					3,248				2,542
Operating Income				$	1,992			$	931
Total other expense					4,569				(8,193	)
Net Income (Loss)				$	6,561			$	(7,262	)
NON-GAAP ADJUSTED EBITDA
FOR THE QUARTER ENDED JUNE 30, 2024 AND 2023
(in thousands)					2024				2023
Net Income (Loss)				$	6,561			$	(7,262	)
Non-GAAP Adjustments:
Interest expense					3,783				4,381
Depreciation and amortization					262				257
EBITDA					10,606				(2,624	)
Non-GAAP Adjustments for Adjusted EBITDA:
Change in fair value of derivative liabilities					(3,717	)			3,821
Other non-cash or non-recurring charges:
Gain on extinguishment of debt					(5,310	)			-
Release of historical accrued expenses					(579	)			(1,250	)
Shares for services					-				224
License and option agreement					-				-
Prepaid legal fees expensed from termination of Merger Agreement					457				-
Adjusted EBITDA				$	1,457			$	171

PART I - FINANCIAL INFORMATION
SANUWAVE HEALTH, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)			June 30, 2024				December 31, 2023
ASSETS
Current Assets:
	Cash		$	2,460			$	1,797
	Accounts receivable, net of allowance of $1,237 and $1,237, respectively			3,154				3,314
	Inventory			2,731				2,951
	Prepaid expenses and other current assets			379				1,722
Total Current Assets				8,724				9,784
Non-Current Assets:
	Property, equipment and right of use assets, net			947				938
	Intangible assets, net			4,082				4,434
	Goodwill			7,260				7,260
Total Non-Current Assets				12,289				12,632
Total Assets			$	21,013			$	22,416
LIABILITIES
Current Liabilities:
	Senior secured debt, in default		$	23,424			$	18,278
	Convertible promissory notes payable			3,953				5,404
	Convertible promissory notes payable, related parties			2,454				1,705
	Asset-backed secured promissory notes payable			-				3,117
	Asset-backed secured promissory notes payable, related parties			-				1,458
	Promissory note payable, related party			500				-
	Accounts payable			3,891				5,705
	Accrued expenses			4,794				5,999
	Factoring liabilities			2,321				1,490
	Warrant liability			16,864				14,447
	Accrued interest			396				5,444
	Accrued interest, related parties			841				669
	Current portion of contract liabilities			130				92
	Other			397				947
Total Current Liabilities				59,965				64,755
Non-Current Liabilities:
	Lease liabilities			304				492
	Contract liabilities			350				347
Total Non-Current Liabilities				654				839
Total Liabilities			$	60,619			$	65,594
STOCKHOLDERS' DEFICIT
Preferred Stock, par value $0.001, 5,000,000 shares authorized; 6,175 shares Series A, 293 shares Series B, 90 shares Series C and 8 shares Series D authorized; no shares issued and outstanding at June 30, 2024 and December 31, 2023			$	-			$	-
Common stock, par value $0.001, 2,500,000,000 shares authorized; 1,181,272,961 and 1,140,559,527 issued and outstanding at June 30, 2024 and December 31, 2023, respectively				1,182				1,140
Additional paid-in capital				177,218				175,842
Accumulated deficit				(218,016	)			(220,049	)
Accumulated other comprehensive loss				10				(111	)
Total Stockholders' Deficit				(39,606	)			(43,178	)
Total Liabilities and Stockholders' Deficit			$	21,013			$	22,416

SANUWAVE HEALTH, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
		Three Months Ended June 30,								Six Months Ended June 30,
(In thousands, except share and per share data)			2024				2023				2024				2023
Revenue		$	7,162			$	4,675			$	12,948			$	8,450
Cost of revenues			1,922				1,202				3,506				2,464
Gross Margin			5,240				3,473				9,442				5,986
Operating Expenses:
	General and administrative		1,839				1,238				5,514				3,997
	Selling and marketing		1,034				978				2,266				2,390
	Research and development		195				139				358				270
	Depreciation and amortization		180				187				362				376
Total Operating Expenses			3,248				2,542				8,500				7,033
Operating Income (Loss)			1,992				931				942				(1,047	)
Other Income (Expense)
	Interest expense		(3,396	)			(3,706	)			(6,633	)			(7,218	)
	Interest expense, related party		(387	)			(675	)			(710	)			(1,441	)
	Loss on extinguishment of debt		5,310				-				5,205				-
	Change in fair value of derivative liabilities		3,717				(3,821	)			1,216				(10,618	)
	Other expense		(685	)			9				(787	)			(18	)
	Other income		10				-				2,800				-
Total Other Expense			4,569				(8,193	)			1,091				(19,295	)
Net Income (Loss)		$	6,561			$	(7,262	)		$	2,033			$	(20,342	)
Other Comprehensive Loss
	Foreign currency translation adjustments		10				(9	)			121				(13	)
Total Comprehensive Income (Loss)		$	6,571			$	(7,271	)		$	2,154			$	(20,355	)

SANUWAVE HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT
(In thousands, except share data)
Six Months Ended June 30, 2024
		Common Stock
		Shares Issued and Outstanding			Par Value			Additional Paid-in Capital			Accumulated Deficit				Accumulated Other Comprehensive Loss				Total
Balances as of December 31, 2023			1,140,559,527		$	1,140		$	175,842		$	(220,049	)		$	(111	)		$	(43,178	)
	Shares issued for settlement of warrants		5,414,815			6			-			-				-				6
	Shares issued for settlement of warrants		35,298,619			36			1,376.00			-				-				1,412
	Foreign currency translation adjustment		-			-			-			-				121				121
	Net Income		-			-			-			2,033				-				2,033
Balances as of June 30, 2024			1,181,272,961		$	1,182		$	177,218		$	(218,016	)		$	10			$	(39,606	)
Six Months Ended June 30, 2023
		Common Stock
		Shares Issued and Outstanding			Par Value			Additional Paid-in Capital			Accumulated Deficit				Accumulated Other Comprehensive Loss				Total
Balances as of December 31, 2022			548,737,651		$	549		$	152,750		$	(194,242	)		$	(67	)		$	(41,010	)
	Shares issued for services		12,900,000			13			514			-				-				527
	Foreign currency translation adjustment		-			-			-			-				(13	)			(13	)
	Net Income		-			-			-			(20,342	)			-				(20,342	)
Balances as of June 30, 2023			561,637,651		$	562		$	153,264		$	(214,584	)		$	(80	)		$	(60,838	)
Three Months Ended June 30, 2024
		Common Stock
		Shares Issued and Outstanding			Par Value			Additional Paid-in Capital			Accumulated Deficit				Accumulated Other Comprehensive Loss				Total
Balances as of March 31, 2024			1,140,559,527		$	1,140		$	175,842		$	(224,577	)		$	-			$	(47,595	)
	Shares issued for settlement of warrants		5,414,815			6			-			-				-				6
	Shares issued for settlement of debt and warrants		35,298,619			36			1,376			-				-				1,412
	Foreign currency translation adjustment		-			-			-			-				10				10
	Net Income		-			-			-			6,561				-				6,561
Balances as of June 30, 2024		$	1,181,272,961		$	1,182.00		$	177,218		$	(218,016	)		$	10.00			$	(39,606	)
Three Months Ended June 30, 2023
		Common Stock
		Shares Issued and Outstanding			Par Value			Additional Paid-in Capital			Accumulated Deficit				Accumulated Other Comprehensive Loss				Total
Balances as of March 31, 2023			555,637,651		$	556		$	153,046		$	(207,322	)		$	(71	)		$	(53,791	)
	Shares issued for services		6,000,000			6			218			-				-				224
	Foreign currency translation adjustment		-			-			-			-				(9	)			(9	)
	Net Income		-			-			-			(7,262	)			-				(7,262	)
Balances as of June 30, 2024			561,637,651		$	562		$	153,264		$	(214,584	)		$	(80	)		$	(60,838	)

SANUWAVE HEALTH, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
				Six Months Ended June 30,
(In thousands)				2024			2023
Cash Flows - Operating Activities:
Net income (loss)				2,033			(20,342	)
	Adjustments to reconcile net loss to net cash used by operating activities
		Depreciation and amortization		480			515
		Bad debt expense		99			313
		Shares issued for services		-			224
		Gain on extinguishment of debt		(5,205	)		-
		Change in fair value of derivative liabilities		(1,216	)		10,618
		Amortization of debt issuance and debt discounts		3,274			3,955
		Accrued interest		1,859			3,606
		Changes in operating assets and liabilities
			Accounts receivable	(340	)		898
			Inventory	220			(31	)
			Prepaid expenses and other assets	118			(336	)
			Accounts payable	(1,259	)		718
			Accrued expenses	328			(1,337	)
			Contract liabilites	41			(16	)
Net Cash Provided by/ (Used in) Operating Activities				432			(1,215	)
Cash Flows - Investing Activities
	Purchase of property and equipment			(206	)		(169	)
Net Cash Flows Used In Investing Activities				(206	)		(169	)
Cash Flows - Financing Activities
	Proceeds from convertible promissory notes			-			1,202
	Payment of note payable			(2,175	)		-
	Proceeds from convertible notes payable			1,300			-
	Proceeds from promissory note payable, related party			500			-
	Proceeds from bridge notes advance			-			1,476
	Proceeds/(Payments) from factoring, net			831			(1,167	)
	Principal payments on finance leases			(140	)		(85	)
Net Cash Flows Provided by /(Used In) Financing Activities				316			1,426
Effect of Exchange Rates on Cash				121			(13	)
Net Change in Cash During Period				663			29
Cash at Beginning of Period				1,797			1,153
Cash at End of Period				2,460			1,182
Supplemental Information:
	Cash paid for interest			2,055			908
Non-Cash Investing and Financing Activities:
	Shares issued for settlement of debt and warrants			1,412			-
	Write off deferred merger costs			1,226			-
	Warrants issued in conjunction with convertible promissory notes			3,633			570
	Capitalize default interest into Senior secured debt			3,850			-
	Conversion of asset-backed secured promissory notes to convertible promissory notes			4,584			-
	Embedded conversion feature on convertible promissory notes payable			-			157
	Common shares issued for advisory shares			-			302

FAQ

What was SANUWAVE's revenue for Q2 2024?

SANUWAVE's revenue for Q2 2024 was $7.2 million, representing a 53% increase compared to Q2 2023.

How many UltraMist® systems did SANUWAVE sell in Q2 2024?

SANUWAVE sold 72 UltraMist® systems in Q2 2024, up from 49 in Q2 2023 and 43 in Q1 2024.

What is SANUWAVE's revenue guidance for Q3 2024?

SANUWAVE expects revenue growth of 65-75% for Q3 2024 compared to Q3 2023, forecasting revenues between $8-8.5 million.

What was SANUWAVE's net income for Q2 2024?

SANUWAVE reported a net income of $6.6 million for Q2 2024, compared to a net loss of $7.3 million in Q2 2023.

What is SANUWAVE's stock symbol?

SANUWAVE Health's stock symbol is SNWV, and it trades on the OTCQB market.